FOLH1 and prostate cancer: First constructs in the Fc-silenced Fab-VH-Fc format by the proprietary platform UniAbs (Teneobio) entered clinical testing recently, with anti-CD19/CD3 TNB-486 targeting B-NHL (NCT04594642) and anti-PSMA/CD3 TNB-585 targeting prostate cancer (NCT04740034).